 Relay Therapeutics RLY-2608 is the first pan-allosteric PIKCA mutation inhibitor and has shown promise in preclinical studies, including better safety vs. Piqray competition. Phase 1 dose escalation data for RLY-2608 is expected in the first half of 2023. The product candidate has the potential to be a blockbuster drug. 